1 of 0
Contact us about this trial
Active, not recruiting
A research study to compare semaglutide to insulin aspart, when taken together with metformin and insulin glargine, in people with type 2 diabetes
Trial ID :

NN9535-4386

NCT Number :

NCT03689374

EudraCT Number :

2017-003219-20

Trial Overview:
Condition

Diabetes Mellitus, Type 2

Treatment

Drug: Semaglutide

Drug: Insulin aspart

Drug: Insulin glargine U100

Study Type

Interventional

Trial Duration
Oct 12018
to
Feb 222021
PARTICIPATION
DURATION
Unknown
Phase
III

This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant's blood sugar gets under or over certain values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor.

Are you eligible?
GENDER

All

AGE
18+years
Back to top
Contact us about this trial